A 2024 randomized trial tested NMN in older adults. One result was expected. Another was much more interesting.
NMN has become one of the most discussed compounds in longevity research but what happens when researchers move beyond laboratory studies and actually test it in humans?
A 2024 randomized, double-blind, placebo-controlled study examined 250 mg of NMN daily for 12 weeks in 60 older adults.
The researchers looked at several things, including blood NAD⁺ levels, physical performance, walking ability, sleep quality, and stress.
The results were interesting but perhaps not for the reason you might expect.
The study found that NMN increased blood NAD⁺ and related metabolites. It also found differences in a 4-meter walking test and certain measures of sleep quality. However, the study's primary stepping-test outcome was not significantly different between the NMN and placebo groups.
So what actually happened?
Let's look at the research without the hype.
1. Why Are Researchers Studying NAD⁺?
Before talking about NMN, we need to understand NAD⁺.
Nicotinamide adenine dinucleotide, or NAD⁺, is a molecule found throughout the body and is involved in fundamental cellular processes, including energy metabolism and other biological reactions.
Because NAD⁺ levels and metabolism change with age, researchers have become interested in whether nutritional strategies can influence NAD⁺ availability.
That's where NMN (nicotinamide mononucleotide) comes into the picture.
NMN is a precursor involved in the body's NAD⁺ biosynthesis pathway.
The important question isn't simply:
"Can NMN increase NAD⁺?"
Researchers also want to know:
"Does increasing NAD⁺ translate into measurable changes in human function?"
That's much harder to answer.
2. What Did the Researchers Actually Test?
The study was designed as a:
- Randomized trial
- Double-blind study
- Placebo-controlled study
- Parallel-group comparison
There were 60 older adults, randomly assigned to either an NMN group or placebo group.
The NMN group consumed 250 mg of NMN per day for 12 weeks.
Researchers assessed participants at the beginning of the study and again during the intervention.
They measured blood NAD-related metabolites, physical performance, sleep, and stress-related outcomes.
This matters because randomized, placebo-controlled trials can provide stronger evidence than simply observing people who already choose to take supplements.
3. What Happened to NAD⁺?
This was one of the clearest findings.
After 12 weeks, participants taking NMN had significantly higher blood levels of NAD⁺ and related metabolites compared with the placebo group.
In other words, the intervention successfully changed the biological marker researchers were targeting.
That's important but it is also where we need to be careful.
Increasing a biomarker does not automatically mean that a supplement improves every aspect of health or slows aging.
The next question is much more interesting:
Did anything measurable happen to physical performance and sleep?
4. What Happened to Walking Performance?
The researchers used several physical-function assessments.
One of them was a 4-meter walking test.
After 12 weeks, the NMN group had a significantly shorter 4-meter walking time compared with the placebo group, meaning they completed the test faster.
The researchers also observed an association between changes in 4-meter walking time and changes in blood NAD⁺ and certain NAD-related metabolites.
But there is an important detail that shouldn't be skipped.
The primary outcome did not show a significant difference.
The primary physical-function measure was a stepping test, and researchers reported no significant difference between the NMN and placebo groups at either 4 or 12 weeks.
The walking result was a secondary outcome.
That distinction matters because it prevents us from turning one interesting finding into a much bigger claim than the study actually supports.
5. And Then There Was Sleep
This was perhaps the more unexpected part of the study.
Researchers also evaluated sleep using the Pittsburgh Sleep Quality Index (PSQI).
After 12 weeks, the NMN group showed improvements in certain sleep-quality measures compared with placebo, including:
- Daytime dysfunction
- Global PSQI score
The researchers therefore reported improved sleep quality in the NMN group.
This doesn't mean NMN should be considered a sleep treatment.
It does, however, provide another interesting human research signal worth investigating.
6. What Did the Study NOT Prove?
This may be the most important section.
The study did not prove that NMN reverses aging.
It did not demonstrate that NMN extends human lifespan.
It did not establish that NMN prevents age-related disease.
And it did not show that everyone taking NMN will experience better sleep or faster walking.
Instead, it showed that in this particular 12-week trial, 250 mg/day of NMN increased blood NAD⁺ and related metabolites, while certain secondary measures of walking performance and sleep also differed between groups.
That's already interesting.
We don't need to make the result bigger than it is.
7. Why This Trial Matters for Longevity Research
The fascinating part of this study isn't that NMN suddenly became a miracle longevity molecule.
It's that researchers were able to move from a biological hypothesis to measurable outcomes in humans.
The research pathway looks something like this:
NMN → NAD⁺ metabolism → measurable biological changes → possible functional outcomes
But every arrow requires investigation.
That's why human clinical trials are so important.
A change in NAD⁺ is interesting.
A change in a walking test is interesting.
A change in sleep-quality scores is interesting.
But researchers need larger and longer studies to determine how meaningful these findings are over the long term.
8. How Does This Fit Into the Bigger NAD⁺ Picture?
NAD⁺ isn't simply an "energy molecule."
It participates in numerous cellular processes, including reactions involved in metabolism and cellular maintenance.
This is one reason NAD⁺ biology has become such an active area of aging research.
NMN is being studied because it is a precursor in NAD⁺ biosynthesis.
But the goal of responsible longevity science isn't to chase a single molecule.
It's to understand whether influencing biological pathways can translate into meaningful improvements in human health and function.
And that's exactly why trials like this one are worth paying attention to.
9. Where NMN Fits
For people interested in healthy aging, NMN is best viewed as a research-backed nutritional compound being investigated for its effects on NAD⁺ biology, rather than as a proven anti-aging treatment.
Aeternum NMN is designed for people who want to incorporate NMN into a broader healthy-aging routine.
The foundation still matters:
Exercise. Protein. Sleep. Balanced nutrition. Stress management. Consistency.
A supplement shouldn't replace those fundamentals.
It should complement them.
And as the science develops, human clinical trials can help us understand where NMN may—and may not—fit into that picture.
The Takeaway
The 2024 trial gave us a surprisingly nuanced answer.
Yes, NMN increased blood NAD⁺ and related metabolites.
Yes, researchers observed differences in a 4-meter walking test and certain measures of sleep quality.
No, the primary stepping-test outcome was significantly different between groups.
And no, this single 12-week study doesn't prove that NMN reverses aging or extends lifespan.
That's exactly what makes the research interesting.
Longevity science isn't about finding one magic answer.
It's about following the evidence one human study at a time.
Want to Explore NMN After Reading the Research?
If you're curious about NMN and want to explore the science for yourself, discover Aeternum NMN and learn more about how NMN fits into the broader conversation around NAD⁺ and healthy aging.
Limited-time offer: Aeternum NMN is currently included in the 24% OFF sitewide campaign.
Use code LONGEVITY24 at checkout.
Explore Aeternum NMN and build your healthy-aging routine while the offer is available.
The Human Study Behind This Article
Morifuji M, Higashi S, Ebihara S, Nagata M.
Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.
PubMed ID: 38789831
https://pubmed.ncbi.nlm.nih.gov/38789831/
Study note: The authors reported that several were employees of Meiji Holdings Co., Ltd., which is relevant when interpreting the findings.